DrugDashboards

Inlexzo

gemcitabine intravesical · GEMCITABINE 225 mg/1 · System · Intravesical · Janssen Biotech, Inc

NDC 57894-0225-01 · 1 SYSTEM in 1 BOX · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$72,984.24per billing unit (225 MG)HCPCS J9183 · Jul 1, 2026
  • Federal ceiling (Big4)$52,666.23per unitJ & J Health Care Systems on behalf of Janssen Biotech Inc. · Feb 20, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$69,000.00
Reported to Texas DSHS · 2026 annual filing · Johnson & Johnson Health Care Systems Inc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 225 MG
$72984.241
HCPCS J9183 · Jul 1, 2026 quarter · typically ASP + 6%

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA219683
TE code
Approval date
Sep 9, 2025
Patents / exclusivity
6 patents, 1 exclusivities
TypeNumber / codeExpires
exclusivityNPSep 9, 2028
patent12636300Nov 7, 2038
patent10729823Aug 19, 2034
patent12447241Aug 19, 2034
patent8679094Apr 15, 2032
patent12576253Dec 17, 2030
patent12403086Jun 28, 2030

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of gemcitabine intravesical (System)

LabelerStrengthFirst seenLast seen
Janssen Biotech, IncGEMCITABINE 225 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Inlexzo — NDC 57894-0225-01," retrieved September 3, 2026, https://drugdashboards.com/drug/57894022501.

Free to cite with attribution — see how the data is put together.